What Are Ozempic and Wegovy?
Ozempic and Wegovy are brand names for semaglutide, a once-weekly injectable medication that belongs to the GLP-1 receptor agonist class.
Ozempic is FDA-approved for type 2 diabetes.
Wegovy is FDA-approved specifically for chronic weight management in adults with obesity or overweight with related health conditions.
Both work through the same biological mechanism — mimicking the natural GLP-1 hormone that regulates appetite, digestion, and blood sugar.
👉 FDA prescribing information:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/215256s000lbl.pdf
How Semaglutide Works for Weight Loss
Semaglutide targets the body’s natural appetite regulation system rather than relying on stimulant effects or calorie blocking.
After injection, it:
Reduces hunger signals in the brain
Increases feelings of fullness
Slows stomach emptying
Stabilizes blood sugar levels
Many patients describe a dramatic reduction in “food noise,” meaning they think about food less often and feel satisfied with smaller portions.
This biological effect explains why semaglutide supports sustained weight loss rather than short-term dieting.
How Much Weight Can You Lose on Semaglutide?
The FDA approval for weight management was based on the STEP clinical trial program, one of the largest obesity drug studies ever conducted.
In STEP-1, participants receiving weekly semaglutide injections lost an average of about 15% of total body weight over 68 weeks.
👉 STEP-1 Trial (NEJM):
https://www.nejm.org/doi/full/10.1056/NEJMoa2032183
For example, a person weighing 220 pounds could potentially lose around 30–35 pounds with sustained therapy.
These results significantly exceeded earlier FDA-approved weight-loss medications.
Real-World Weight Loss Results
Clinical trials show what happens under controlled conditions. Real-world studies reveal how semaglutide performs in everyday practice.
Large observational studies in the United States show that many patients achieve clinically meaningful weight loss within the first year of treatment.
👉 Real-world outcomes study (JAMA Network Open):
https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2799388
Insurance claims data indicates that patients who remain on therapy for at least 12 months often experience double-digit percentage weight reduction.
However, real-world data also shows that discontinuation rates can be higher due to:
Cost and insurance barriers
Early gastrointestinal side effects
Supply shortages
Benefits Beyond Weight Loss
Semaglutide provides significant metabolic benefits beyond reducing body weight.
FDA-reviewed studies show improvements in:
Blood sugar control (HbA1c)
Blood pressure
Cholesterol levels
Cardiovascular risk markers
A major cardiovascular outcomes trial demonstrated reduced risk of heart attack and stroke in patients with type 2 diabetes.
👉 Cardiovascular outcomes trial (NEJM):
https://www.nejm.org/doi/full/10.1056/NEJMoa1607141
These benefits are especially important because obesity and diabetes significantly increase cardiovascular risk.
Common Side Effects of Ozempic and Wegovy
The most frequently reported side effects include:
Nausea
Vomiting
Diarrhea
Constipation
Early fullness
These symptoms usually occur during dose escalation and often improve as the body adapts.
Gradual dose increases are essential to minimize discomfort.
FDA Safety Warnings
According to FDA labeling, semaglutide carries important safety considerations.
These include:
Risk of pancreatitis
Gastrointestinal adverse reactions
Potential thyroid C-cell tumors observed in rodent studies
Semaglutide should not be used in individuals with a personal or family history of medullary thyroid carcinoma or MEN2 syndrome.
Medical supervision is essential throughout treatment.
What Happens If You Stop Semaglutide?
Obesity is a chronic condition influenced by biological adaptations.
Studies show that stopping semaglutide often leads to partial weight regain because the hormonal drivers of hunger remain active.
👉 Weight regain study (STEP-4 extension):
https://jamanetwork.com/journals/jama/fullarticle/2783904
This is why semaglutide is typically considered a long-term therapy rather than a short-term solution.
Who Is a Candidate for Semaglutide?
Semaglutide may be appropriate for adults who:
Have obesity (BMI ≥30)
Have overweight (BMI ≥27) with health conditions
Have type 2 diabetes needing weight reduction
Struggle with persistent hunger despite lifestyle changes
A healthcare provider determines eligibility and monitors safety.
Final Thoughts
Semaglutide has reshaped modern obesity treatment by addressing the hormonal drivers of appetite and metabolism.
By reducing hunger biologically and improving metabolic health, it enables patients to achieve sustained weight loss in a medically supported way.
When combined with healthy nutrition, physical activity, and ongoing medical care, it can be a powerful tool for long-term health improvement.